Bank Of New York Mellon Corp Aligos Therapeutics, Inc. Transaction History

Bank Of New York Mellon Corp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.04 - $2.14 $53,678 - $110,453	-51,614 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$11.48 - $17.69 $35,737 - $55,068	3,113 Added 6.42%	51,614 $612,000
Q3 2021 Nov 12, 2021	BUY	$14.57 - $17.72 $44,875 - $54,577	3,080 Added 6.78%	48,501 $752,000
Q2 2021 Aug 11, 2021	BUY	$20.3 - $33.6 $276,973 - $458,438	13,644 Added 42.94%	45,421 $926,000
Q1 2021 May 13, 2021	BUY	$19.1 - $34.94 $31,839 - $58,244	1,667 Added 5.54%	31,777 $722,000
Q4 2020 Feb 09, 2021	BUY	$13.2 - $32.74 $397,452 - $985,801	30,110 New	30,110 $832,000

227K

Ticker ALGS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,717,000
Market Cap $1.3B
Description
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.